Arcutis Biotherapeutics Sees 122% Rise in Net Product Revenue

By Ahmed Jameison • Tuesday, October 28 15:38 • Permanent Link

Arcutis Biotherapeutics, Inc. has reported its financial results for the third quarter of 2025, outlining a strategy for sustained long-term growth. The company recorded a significant increase in net product revenue for its flagship product, Zoryve® (roflumilast), with a 122% rise compared to the third quarter of 2024 and a 22% increase compared to the second quarter of 2025. The company also provided initial 2026 full-year net product sales guidance of $455–$470 million.

The net product sales for Zoryve in the third quarter of 2025 were $99.2 million, reflecting a 22% sequential growth over the second quarter of 2025 and a 122% year-over-year growth. This sequential growth was primarily driven by increasing demand across products, the launch of Zoryve foam 0.3% in plaque psoriasis of the scalp and body, and improved gross-to-net pricing.

Furthermore, the company received FDA approval for Zoryve cream 0.05% for the treatment of atopic dermatitis in children ages 2 to 5 in October 2025. The company also initiated phase 2 proof-of-concept studies with Zoryve foam 0.3% for the treatment of vitiligo and hidradenitis suppurativa, indicating potential additional indications for Zoryve.

In terms of financial performance, product revenues for the quarter ended September 30, 2025, were $99.2 million compared to $44.8 million for the corresponding period in 2024, representing a substantial increase. The year-over-year increase was primarily due to increased unit demand, and gross-to-net rates remained favorable for Zoryve, driven by a high percentage of prescriptions being reimbursed.

The company's net income for the quarter ended September 30, 2025, was $7.4 million, or $0.06 per basic and diluted earnings per share, compared to a net loss of $41.5 million, or $0.33 per basic and diluted loss per share, for the corresponding period in 2024. Additionally, Arcutis anticipates net product revenue of between $455 million and $470 million for the full year 2026.

Following these announcements, the company's shares moved -2.34%, and are now trading at a price of $19.64. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.